Compare American International Group Inc (AIG) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

AIG trades at $78.78, down 1.49% on the day, with a neutral technical stance as RSI readings near 42 suggest balanced momentum. The stock shows solid fundamentals with a P/E of 14.38 and recent earnings beats, including Q2 2026 EPS of $2.00 versus $1.92 expected. Revenue stability around $26.8 billion in 2025 and a net income margin of 11.88% reflect disciplined underwriting and expense control, though investment income headwinds persist. Analyst consensus price target is $88.90, implying potential upside, supported by a 39% buy rating among coverage.

Outlook remains cautiously optimistic given earnings consistency and undervaluation relative to peers, but risks include competitive pricing pressure and macroeconomic volatility affecting insurance demand. The dividend yield of approximately 2.5% adds income appeal, yet high beta exposure may lead to amplified swings in broader market downturns, warranting monitoring of Q3 2026 results for sustained growth catalysts.

CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.

The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.